Recently, PET imaging with other radiopharmaceuticals is also being investigated in terms of radiomic analysis, including radiolabeled prostate-specific membrane antigen (PSMA) in prostate cancer patients [12]. This evidence concerns the gene FOLH1 and prostate cancer.